exalenz bioscience ltd
(EXEN:Tel Aviv Stock Exchange)
Scott L. Friedman M.D.
Member of Scientific Advisory Board, Exalenz Bioscience Ltd
|Age||Total Calculated Compensation||This person is connected to 41 board members in 4 different organizations across 5 different industries.|
See Board Relationships
Dr. Scott L. Friedman, M.D., serves as the Chief of the Division of Liver Diseases and Professor of Medicine at Mount Sinai School of Medicine in New York. At Mount Sinai School of Medicine in New York, Dr. Friedman is responsible for the discovery of a novel tumor suppressor gene, KLF6 that is inactivated in a number of human cancers, including primary liver cancer. He has performed pioneering research into the underlying causes of scarring, or fibrosis, associated ...
4 Ha’maayan StreetPhone: 972 8 973 7500
Modiin, -- 71700
Fax: 972 8 973 7501
Board Members Memberships*There is no Board Members Memberships data available.
Unknown/Other Education 1979
Mount Sinai School Of Medicine
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|There is no Competitor Compensation data available.|